Terms: = Prostate cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
12 results:
1. Somatic aberrations of BRCA1 gene are associated with ALDH1, egfr, and tumor progression in prostate cancer.
Omari A; Nastały P; Stoupiec S; Bałabas A; Dąbrowska M; Bielińska B; Huss S; Pantel K; Semjonow A; Eltze E; Brandt B; Bednarz-Knoll N
Int J Cancer; 2019 Feb; 144(3):607-614. PubMed ID: 30265376
[TBL] [Abstract] [Full Text] [Related]
2. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.
Chang YP; Chen YM; Lai CH; Lin CY; Fang WF; Huang CH; Li SH; Chen HC; Wang CC; Lin MC
PLoS One; 2017; 12(6):e0178676. PubMed ID: 28591157
[TBL] [Abstract] [Full Text] [Related]
3. Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men.
Kachroo N; Warren AY; Gnanapragasam VJ
BMC Cancer; 2014 Sep; 14():673. PubMed ID: 25227682
[TBL] [Abstract] [Full Text] [Related]
4. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Sridhar SS; Hotte SJ; Chin JL; Hudes GR; Gregg R; Trachtenberg J; Wang L; Tran-Thanh D; Pham NA; Tsao MS; Hedley D; Dancey JE; Moore MJ
Am J Clin Oncol; 2010 Dec; 33(6):609-13. PubMed ID: 20042973
[TBL] [Abstract] [Full Text] [Related]
5. Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells.
Kajanne R; Miettinen P; Tenhunen M; Leppä S
Int J Oncol; 2009 Nov; 35(5):1175-82. PubMed ID: 19787273
[TBL] [Abstract] [Full Text] [Related]
6. Epidermal growth factor receptor (egfr) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
Marks RA; Zhang S; Montironi R; McCarthy RP; MacLennan GT; Lopez-Beltran A; Jiang Z; Zhou H; Zheng S; Davidson DD; Baldridge LA; Cheng L
Prostate; 2008 Jun; 68(9):919-23. PubMed ID: 18409189
[TBL] [Abstract] [Full Text] [Related]
7. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Kim ES
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
[TBL] [Abstract] [Full Text] [Related]
8. [EGF receptors in urological cancer. Molecular basis and therapeutic involvements].
Paule B; Brion N
Ann Med Interne (Paris); 2003 Nov; 154(7):448-56. PubMed ID: 14732836
[TBL] [Abstract] [Full Text] [Related]
9. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract] [Full Text] [Related]
10. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract] [Full Text] [Related]
11. Predictive laboratory diagnostics in oncology utilizing blood-borne cancer cells--current best practice and unmet needs.
Brandt BH; Schmidt H; de Angelis G; Zänker KS
Cancer Lett; 2001 Jan; 162 Suppl():S11-S16. PubMed ID: 11164185
[TBL] [Abstract] [Full Text] [Related]
12. A potential autocrine loop between heregulin-alpha and erbb-3 receptor in human prostatic adenocarcinoma.
Leung HY; Weston J; Gullick WJ; Williams G
Br J Urol; 1997 Feb; 79(2):212-6. PubMed ID: 9052472
[TBL] [Abstract] [Full Text] [Related]
